Unrestricted insurance coverage of buprenorphine formulations remains sparse in comparison to conventional opioids
Access to buprenorphine formulations was limited in comparison to other opioids. This study emphasizes a need for commercial and Medicare health insurance plans to broaden buprenorphine coverage.
Authors
- Taif Mukhdomi (ORCID: https://orcid.org/0000-0002-1140-4540)
- Nidhi Bhaskar
- Junaid Mukhdomi (ORCID: https://orcid.org/0000-0003-4878-1240)
- Bennett Andrassy (ORCID: https://orcid.org/0009-0000-5743-7623)
- Marcus Harris
Institutions
- Brown University (US)
- Pain Management Institute (US)
- Bennett Aerospace (United States) (US)
- Pain Labs
Publication Details
- Journal
- Regional Anesthesia & Pain Medicine
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1136/rapm-2024-106306
- Citations
- 1
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.88